by Dr. Ed Weber | Sep 29, 2021 | PCa Commentary
Metastatic Hormone Sensitive Prostate Cancer refers to cancers which are found to have metastasized at diagnosis prior to primary treatment and therefore have not been exposed to testosterone deprivation. The incidence of this stage of cancer at diagnosis increased... by Dr. Ed Weber | Aug 25, 2021 | PCa Commentary
“Pylarify” is a recently FDA approved tracer for imaging the prostate specific membrane antigen (PSMA) displayed on ~95% of prostate cancer cells. This urea-based radiotracer combines the small molecule DCFPyL, a PSMA targeting agent, with the positron-emitting... by Dr. Ed Weber | Jul 27, 2021 | PCa Commentary, Uncategorized
Hot flashes are an especially unpleasant adverse effect of androgen deprivation therapy (ADT). They occur with varying intensity in about 70% of men undergoing treatment. Hot flashes (also termed hot flushes) are experienced as a feeling of increased of body heat... by Dr. Ed Weber | Jun 30, 2021 | PCa Commentary
Neuroendocrine Prostate Cancer: What is it? Under the sustained and intense suppression of testosterone with Lupron or Degarelix – and now with the even stronger suppression with drugs like Xtandi and Zytiga, prostatic adenocarcinoma may undergo a... by Dr. Ed Weber | May 28, 2021 | PCa Commentary
Radioligand Therapy (RLT) targeted with the radionuclide Lutetium 177 or Actinium 225 has been found in early studies to be promising, safe and effective. A Gestault of results has generally shown about a 50% PSA decline in 50% of patients and a median...